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, and FcγR gene polymorphism can impact the clinical response to trastuzumab (6) . NK cells constitutively express FcγRIIIA (CD16) and are the major effectors of ADCC (7) .
Therefore the function of NK cells may impact the efficacy of ADCC and clinical response to trastuzumab (8) . Unfortunately, NK cell function is frequently impaired in cancer patients as compared to healthy donors (9) (10) (11) , and lytic function of NK cells in patients with advanced disease (stages II, III, and IV) is even lower than in those with limited disease (stage I) (12) . Therefore novel approaches that can enhance NK cell function and improve ADCC would potentially benefit many cancer patients receiving mAb therapy.
Research. (14) . Both types of NK cells have been found to express toll-like receptors (TLRs) (15) . TLR agonists, especially the agonist of TLR3 (poly I:C), TLR7/8 (imiquimod, resiquimod, and 3M-002), and TLR9 (CpG), have been shown to activate NK cells either directly or indirectly via stimulation of accessory cells (15) (16) (17) (18) (19) . A Phase II clinical trial that combines rituximab and 1018 ISS (CpG) has been conducted in patients with relapsed or refractory follicular lymphoma, and the results showed that biologically relevant increase in ADCC was observed in 35% of patients (20) , demonstrating the potential of using TLR agonists to improve mAb therapy.
The effect of TLR2 agonist on NK cell function and ADCC is relatively less well known, although there is some evidence that NK cells can be activated via TLR2 either directly or indirectly via DC (21) (22) (23) as a selective and potent TLR2 agonist and revealed the potential of using a natural product to enhance NK cell function (25) .
The major component of PSK is protein-bound polysaccharide with an approximate molecular weight of 90-100kDa. PSK was approved as a prescription drug for the treatment of cancer in Japan in 1977 (26) . Clinical trials in Japan have shown that oral intake of PSK significantly extended survival at five years or beyond in patients with different types of cancer, especially stomach and colorectal cancer (27) (28) (29) . Using HEK293 cells transfected with different TLRs, we demonstrated that PSK is a selective and potent TLR2 agonist (25) . We further showed that the anti-tumor effect of PSK in a mouse model of breast cancer is dependent on both CD8 T cells and NK cells (25) .
Expanding from our previous findings in mice, the current study was undertaken to investigate the effect of PSK on human NK cells and trastuzumab-mediated ADCC and the potential of using this natural product with TLR2 agonist activity to augment the antitumor effect of trastuzumab. + DC were also sorted from PBMC as control. RNA was isolated from FACS-sorted cells or whole PBMC using RNAqeous4PCR kit (Ambion, TX). cDNAs were prepared using Superscript III reverse transcriptase (Invitrogen). Quantitative PCR was performed using Taqman primer and probe from Applied Biosystems (Foster City, CA) in 384-well plates using an ABI 7900 (Applied Biosystems). Cycling conditions were similar as previously described (30) . The expression of TLR2 mRNA was normalized to hypoxanthine ribosyltransferase (HPRT) using the delta Ct method (30) . Figure 4B ) and decreased levels of IFN-γ in culture supernatant from PBMC ( Figure   4C ). It is noted that there is residual amount of IFN-γ production even when IL-12 is blocked, suggesting that IL-12 independent induction of IFN-γ by PSK may also exist ( Figure 4B and C) . In contrast, PSK-induced TNF-α production by PBMC was not decreased in the presence of anti-IL12 antibody (Supplemental Figure 1) . This could be due to that fact that monocytes and DC can produce large amounts of TNF-α in addition to NK cells. It also suggests that TNF-α production by NK cells could be regulated differently from IFN-γ production by NK, and is independent of IL-12. To confirm that showed that PSK by itself significantly induced the expression of CD25 on purified NK cells ( Figure 4D ), but the effect on IFN-γ production is moderate (not significant by intracellular staining but significant by ELISA measurement, Figure 4E and F). In the presence of IL-12, PSK resulted in enhanced IFN-γ production, which is significantly higher than either PSK or IL-12 single treatment ( Figure 4E and F). These data suggest that PSK-induced IFN-γ production but not CD25 unpregulation is dependent on IL-12.
Experiments using NK-92 cells yielded results consistent to those from purified NK cells showing that the production of IFN-γ in response to PSK is dependent on IL-12 (Supplemental Figure 3) . We also measured the expression of TLR2 on NK cells by FACS analysis and real-time PCR. FACS analysis showed that TLR2 is detectable in 
for Luminex analysis of IL-12 and other cytokines and chemokines. As shown in Figure   5A , PSK significantly induced the production of IL-12p40. PSK also significantly induced other proinflammatory cytokines and chemokines (TNF-α, IL-6, IL-8, MIP-1α, MIP-1β, IL-1α, and IL-1β) from PBMC. The level of cytokine/chemokine induction is similar to our previous observation on the effect of PSK on mouse splenocytes (25) .
Interestingly, this panel of cytokines and chemokines (except IL-12) were also induced in the cytolytic assay when PSK-stimulated PBMC were co-incubated with K562 (Supplemental Figure 5 ), indicating that PSK stimulates the cytokine-secreting and cytolytic activity of NK cells simultaneously.
Luminex analysis was also performed to measure the potential secretion of cytokine/chemokines by PSK-treated purified NK cells. As shown in Figure 5B , PSK induced the production of TNF-α, MIP-1α, and MIP-1β by NK cells. Interestingly, the pattern of induction for these cytokine/chemokines seems to be different from that for IFN-γ ( Figure 4F ) and appears to be independent of IL-12 ( Figure 5B ). The time course of cytokine/chemokine induction in one of the 5 donors tested in Figure 5B was shown in Figure 5C . 
Page 22 of 36 in clinical trials, such as CpG, imiquimod, or poly I:C, is its known safety profile. PSK is a mushroom extract that has been widely used in Asian countries for its immune potentiating and anti-tumor effects. A meta-analysis of data from three randomized clinical trials in Japan in 1,094 patients with colorectal cancer showed that PSK significantly increased both overall survival and disease-free survival of patients with curatively resected colorectal cancer (29) . The anti-tumor effect of PSK has also been demonstrated in other types of cancer, including stomach cancer (27, 47) and lung cancer (48) . To our knowledge, our study represents the first report on the potential of PSK to 
Page 23 of 36 response to trastuzumab, but to other monoclonal antibody therapies as well, such as rituximab for lymphoma and cetuximab for head and neck cancer (8) . Thus, results from the current study could potentially be expanded to other types of cancer. Our study highlights the potential of combining CAM therapy to mainstream cancer therapy for enhanced therapeutic effect.
Research. 
